EGFR and non-small cell lung carcinoma: From existing preclinical and clinical studies, ICIs were generally well tolerated as monotherapy or in combination with chemotherapy or anti-angiogenesis for EGFR-mutant NSCLC patients, and no newly treatment-related adverse events have been observed.